Drugs / Dolcanatide
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial · 1 missed | ||||||
| Phase 1 | NCT03300570 | Jul 2018 → Jan 2019 | colorectal carcinoma | National Cancer Institute (NCI) | Completed | Missed primary |
| Phase 21 trial | ||||||
| Phase 2 | NCT01983306 | Nov 2013 → Sep 2014 | constipation disorder | Bausch Health Americas, Inc. | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT01705938 Comparator | Oct → Dec 2012 | exposure, dental pulp | Bausch Health Americas, Inc. | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Dolcanatide | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03300570 ↗ |
| Known as | Dolcanatida | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545122 ↗ |
| Known as | SP-333 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01705938 ↗ |
| Action | Activate | “Heat-stable enterotoxin receptor agonist” CHEMBL3545122 ↗ |
| Modality | Protein / enzyme biologic | — CHEMBL3545122 ↗ |
| Route | Oral | “orally administered SP-333 tablets” NCT01705938 ↗ |
| Target | GUCY2C | “Heat-stable enterotoxin receptor agonist” CHEMBL3545122 ↗ |